Clinical significance of selected genes variations using targeted deep sequencing in non-small-cell lung cancer
| Autor: | Eman E Farghal, Ayman S El-Deeb, Amgad A. Farhat, Martina R Abdo, Said M. Abdou |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Oncology
medicine.medical_specialty mesenchyme to epithelial transition medicine.medical_treatment on 5 July 2018 presented-atThe work was presented at the Faculty of Medicine Context (language use) medicine.disease_cause Targeted therapy Exon Internal medicine medicine Clinical significance Epidermal growth factor receptor Lung cancer General Environmental Science lcsh:RC705-779 Mutation Chemotherapy biology business.industry General Engineering lcsh:Diseases of the respiratory system Tanta University medicine.disease respiratory tract diseases non-small-cell lung cancer biology.protein General Earth and Planetary Sciences next-generation sequencing epidermal growth factor receptor business |
| Zdroj: | Egyptian Journal of Chest Disease and Tuberculosis, Vol 68, Iss 3, Pp 404-411 (2019) |
| ISSN: | 0422-7638 |
| DOI: | 10.4103/ejcdt.ejcdt_179_18 |
| Popis: | Context Non-small-cell lung cancer (NSCLC) is a heterogeneous disease. Most patients with lung cancer present with inoperable advanced stage and cannot tolerate chemotherapy, so they need targeted therapy, with high effectiveness and less toxicity. Aim The aim of this study was to identify the genetic variations of epidermal growth factor receptor (EGFR) and mesenchyme to epithelial transition (MET) genes in patients with NSCLC and their clinical significance in such cases. Settings and design This is a cross-sectional study. Patients and methods This study was conducted in the chest department and genetic signature center, Tanta University Hospital, on 60 patients of NSCLC who underwent tumor biopsy taking and then DNA isolation, but only 20 patients could continue the study after assessment of their samples for DNA quality. TruSight NSCLC panel was used for detection of different variants in two genes (EGFR and MET). Some patients with NSCLC were subjected to anti-EGFR target therapy. Results Overall, 25% of the patients with NSCLC had EGFR mutation (60% of these mutations are exon 19 deletions, 20% had exon 21 mutation in form of single base mutation, and 20% had exon 20 insertion mutation). Moreover, 10% had MET mutation, in the form of exon 14 mutation, and 5% had both EGFR and MET mutations. Conclusion EGFR and MET are important oncogenic targets for personalized target therapy in NSCLC, so genetic and molecular testing is mandatory for NSCLC cases. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|